First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis
Lutz Renders(TUM Klinikum), Louis A. Matis(Pieris Pharmaceuticals (United States))
Cited by 59
Related Papers
A Role for Complement in Antibody-Mediated Inflammation: C5-Deficient DBA/1 Mice Are Resistant to Collagen-Induced Arthritis
|The Journal of Immunology|2000|193